Natraj Proteins Ltd

As of November 17, 2025, Natraj Proteins is considered undervalued with a valuation grade shift to attractive, featuring a PE ratio of -9.07 and an EV to EBITDA of 34.42, significantly lower than peers like Gokul Agro and Guj. Ambuja Exp, despite a year-to-date return of -14.80% compared to the Sensex's 8.72%, indicating potential for recovery and growth.

Natraj Proteins has experienced significant fluctuations in financial performance, with declining net sales and operating income, but improved cash flow from operations. Despite a positive operating profit in Mar'25, the company continues to face challenges with negative profits before and after tax.

As of October 16, 2025, Natraj Proteins is considered very expensive and overvalued with a PE ratio of -16.45 and an EV to EBITDA of 25.34, significantly underperforming its peers and the Sensex, which highlights its deteriorating valuation outlook.

As of October 14, 2025, Natraj Proteins is considered overvalued with a valuation grade of "expensive," highlighted by a negative PE ratio of -16.48 and an underperformance of -8.30% year-to-date compared to the Sensex's 4.98%, while peers like Gokul Agro and Guj. Ambuja Exp show fair and attractive valuations, respectively.

As of 09-Oct, Natraj Proteins Ltd's stock price is Rs 40.69, up 2.88% today, with significant volatility. While it has outperformed its sector recently, its year-to-date performance lags behind the Sensex, indicating a mixed outlook.

As of 07-Oct, Natraj Proteins Ltd is currently priced at Rs 41.81, reflecting a short-term increase despite a year-to-date decline of 6.26%. The stock shows bullish sentiment with trading above moving averages, but decreased investor participation and underperformance against the Sensex raise concerns about the sustainability of its recent gains.

As of October 1, 2025, Natraj Proteins is considered very expensive and overvalued, with a PE ratio of -14.61 and an EV to EBITDA of 24.88, significantly underperforming its peers and the market.

As of October 1, 2025, Natraj Proteins is considered very expensive and overvalued, with a negative PE ratio of -14.61 and significant financial distress, underperforming against peers and the Sensex.

As of 01-Oct, Natraj Proteins Ltd's stock price is Rs 39.00, down 6.47%, with significant underperformance against its sector and key moving averages. The company faces financial challenges, including operating losses and a high Debt to EBITDA ratio, contributing to a consistent decline in stock performance over the past year and three years.

As of 29-Sep, Natraj Proteins Ltd is currently priced at Rs 41.29, reflecting a daily gain despite a 15.32% decline over the past year and ongoing operational challenges. The stock's performance indicates a lack of investor confidence, with significant underperformance against market benchmarks and concerning financial metrics.

As of September 23, 2025, Natraj Proteins is considered very expensive and overvalued, with a negative PE ratio of -15.18 and poor financial performance indicators compared to peers, despite recent short-term stock outperformance.

As of September 22, 2025, Natraj Proteins is considered undervalued with a PE ratio of -15.55 and a Price to Book Value of 0.48, making it attractive compared to peers like Gokul Agro and Guj. Ambuja Exp, while its recent stock performance has outpaced the Sensex.

As of September 18, 2025, Natraj Proteins is considered overvalued with a PE ratio of -14.99 and an EV to EBITDA of 25.13, significantly underperforming its peers and the Sensex, making it an unfavorable investment.

As of September 17, 2025, Natraj Proteins is considered undervalued with a PE ratio of -15.06 and an attractive valuation grade, indicating a potential buying opportunity despite recent underperformance compared to the Sensex.

As of September 16, 2025, Natraj Proteins is overvalued with a PE ratio of -14.72 and significant financial distress, underperforming its peers and the Sensex, reflected by a -19.59% return compared to the Sensex's -0.73%.